Pricing Log in Create free account

Caris Life Sciences,�Inc. (CAI) vs Protagonist Therapeutics, Inc. (PTGX)

Caris Life Sciences,�Inc. and Protagonist Therapeutics, Inc. are both Biotechnology companies. Protagonist Therapeutics, Inc. is the larger, with a market value of $8.8B against $7.4B — 1.2× the size. Caris Life Sciences,�Inc. trades at the lower P/E: 73.9× against 108×. Caris Life Sciences,�Inc. grew revenue faster over the last twelve months: 68.8% against 34.8%. Protagonist Therapeutics, Inc. has the higher net margin (29.4% vs 9.16%) and the higher return on invested capital (61.8% vs 33.0%). Across the 20 metrics below, Protagonist Therapeutics, Inc. leads on 11 and Caris Life Sciences,�Inc. on 9.

Valuation

Metric CAI PTGX Biotechnology median
P/E 73.94 108.04 10.60
P/S 6.80 30.82 9.40
P/B 11.15 10.33 2.13
Price to free cash flow 246.58 66.56 25.18
EV/EBITDA 40.62 140.44 0.66
EV/Sales 6.44 28.08 9.02
Earnings yield 1.35% 0.93% (32.88%)
Free cash flow yield 0.41% 1.50% (23.13%)

Profitability

Metric CAI PTGX Biotechnology median
Gross margin 69.09% 100.00% 68.51%
Operating margin 13.35% 20.69% 0.00%
Net margin 9.16% 29.40% 0.00%
Free cash flow margin 2.76% 46.31% 0.00%
Return on equity 17.19% 10.98% (51.96%)
Return on assets 8.58% 10.34% (46.06%)
Return on invested capital 32.96% 61.84% 0.00%

Growth

Metric CAI PTGX Biotechnology median
Revenue growth (TTM) 68.84% 34.81% 6.76%
EPS growth (last fiscal year) 69.79% (148.46%) 29.88%
Revenue growth, 5-year CAGR — 9.96% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAI PTGX Biotechnology median
Debt to equity 0.62 0.00 0.00
Current ratio 6.71 21.71 4.97
Net debt to EBITDA (5.23) 3.49 1.01

Dividend

Metric CAI PTGX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CAI PTGX Biotechnology median
Market cap 7.36b 8.75b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack